AOP Health congratulates FROM on its great scientific work in the field of myeloproliferative neoplasms

News provided by
AOP Health
May 16, 2023 15:50 Korea Standard Time

VIENNA--(Business Wire / Korea Newswire)--Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) announced the publication of the latest results from the LOW-PV trial in the NEJM Evidence.

The findings support a paradigm shift in the treatment of patients with Polycythaemia Vera, a rare kind of blood cancer. AOP Orphan Pharmaceuticals GmbH (AOP Health) congratulates Prof. Tiziano Barbui and his team on this success and is pleased to have contributed to FROM’s important work as a reliable research partner.

Find out more about the trial and its results here.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. The claim “Needs. Science. Trust.” sums up the foundation of the Group’s success: establishing trust through a continually high level of investment in research and development and a highly consistent and pragmatic orientation towards the needs of all stakeholders - especially the patients and their families as well as the healthcare professionals treating them.

View source version on


View Korean version of this release


AOP Health Group
DI Isolde Fally
+43-676-500 4048

This is a news release distributed by Korea Newswire on behalf of this company.